JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB269483

Human KRT13 knockout A-431 cell line

Be the first to review this product! Submit a review

|

(0 Publication)

KRT13 KO cell line available to order. KO validated by Next Generation Sequencing, Western blot. Free of charge wild type control available. Knockout achieved by CRISPR/Cas9 X = 5 bp deletion Frameshift: 100%. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
4 Images
Western blot - Human KRT13 knockout A-431 cell line (AB269483)
  • WB

Lab

Western blot - Human KRT13 knockout A-431 cell line (AB269483)

False colour image of Western blot : Anti-Cytokeratin 13 antibody [EPR3671] staining at 1/100000 dilution shown in green; Mouse anti-GAPDH antibody [6C5] (ab8245) loading control staining at 1/20000 dilution shown in red. In Western blot ab92551 was shown to bind specifically to Cytokeratin 13. A band was observed at 51 kDa in wild-type A431 cell lysates with no signal observed at this size in Krt13 knockout cell line ab269483 (knockout cell lysate ab269647). To generate this image wild-type and Krt13 knockout A431 cell lysates were analysed. First samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °. Blots were washed four times in TBS-T incubated with secondary antibodies for 1 h at room temperature washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) at 1/20000 dilution.

All lanes:

Western blot - Anti-Cytokeratin 13 antibody [EPR3671] (<a href='/en-us/products/primary-antibodies/cytokeratin-13-antibody-epr3671-ab92551'>ab92551</a>) at 1/100000 dilution

Lane 1:

Wild-type A431 cell lysate at 20 µg

Lane 2:

KRT13 knockout A431 cell lysate at 20 µg

Lane 2:

Western blot - Human KRT13 knockout A-431 cell line (ab269483)

Predicted band size: 50 kDa

Observed band size: 51 kDa

false

Western blot - Human KRT13 knockout A-431 cell line (AB269483)
  • WB

Lab

Western blot - Human KRT13 knockout A-431 cell line (AB269483)

False colour image of Western blot : Anti-Cytokeratin 13 antibody [AE8] staining at 1 μg/ml shown in green; Rabbit Anti-GAPDH antibody [EPR16891] (ab181602) loading control staining at 1/20000 dilution shown in red. In Western blot ab16112 was shown to bind specifically to Cytokeratin 13. A band was observed at 51 kDa in wild-type A431 cell lysates with no signal observed at this size in Krt13 knockout cell line ab269483 (knockout cell lysate ab269647). To generate this image wild-type and Krt13 knockout A431 cell lysates were analysed. First samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °. Blots were washed four times in TBS-T incubated with secondary antibodies for 1 h at room temperature washed again four times then imaged. Secondary antibodies used were Goat anti-Mouse IgG H&L (IRDye® 800CW) preabsorbed (ab216772) and Goat anti-Rabbit IgG H&L (IRDye® 680RD) preabsorbed (ab216777) at 1/20000 dilution.

All lanes:

Western blot - Anti-Cytokeratin 13 antibody [AE8] (<a href='/en-us/products/primary-antibodies/cytokeratin-13-antibody-ae8-ab16112'>ab16112</a>) at 1 µg/mL

Lane 1:

Wild-type A431 cell lysate at 20 µg

Lane 2:

KRT13 knockout A431 cell lysate at 20 µg

Lane 2:

Western blot - Human KRT13 knockout A-431 cell line (ab269483)

Predicted band size: 50 kDa

Observed band size: 51 kDa

false

Western blot - Human KRT13 knockout A-431 cell line (AB269483)
  • WB

Lab

Western blot - Human KRT13 knockout A-431 cell line (AB269483)

False colour image of Western blot : Anti-Cytokeratin 13 antibody [EPR3672] staining at 1/2000 dilution shown in green; Mouse anti-GAPDH antibody [6C5] (ab8245) loading control staining at 1/20000 dilution shown in red. In Western blot ab133340 was shown to bind specifically to Cytokeratin 13. A band was observed at 51 kDa in wild-type A431 cell lysates with no signal observed at this size in Krt13 knockout cell line ab269483 (knockout cell lysate ab269647). To generate this image wild-type and Krt13 knockout A431 cell lysates were analysed. First samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °. Blots were washed four times in TBS-T incubated with secondary antibodies for 1 h at room temperature washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) at 1/20000 dilution.

All lanes:

Western blot - Anti-Cytokeratin 13 antibody [EPR3672] (<a href='/en-us/products/primary-antibodies/cytokeratin-13-antibody-epr3672-ab133340'>ab133340</a>) at 1/2000 dilution

Lane 1:

Wild-type A431 cell lysate at 20 µg

Lane 2:

KRT13 knockout A431 cell lysate at 20 µg

Lane 2:

Western blot - Human KRT13 knockout A-431 cell line (ab269483)

Predicted band size: 50 kDa

Observed band size: 51 kDa

false

Next Generation Sequencing - Human KRT13 knockout A-431 cell line (AB269483)
  • NGS

Supplier Data

Next Generation Sequencing - Human KRT13 knockout A-431 cell line (AB269483)

Knockout achieved by CRISPR/Cas9; X = 5 bp deletion; Frameshift : 100%

Key facts

Cell type

A-431

Species or organism

Human

Tissue

Skin

Form

Liquid

form

Knockout validation

Next Generation Sequencing,Western blot

Mutation description

Knockout achieved by CRISPR/Cas9 X = 5 bp deletion Frameshift: 100%

Disease

Epidermoid Carcinoma

style
left-column

Complementary Products

Primary Antibodies

AB92551

Anti-Cytokeratin 13 antibody [EPR3671]

RabMAb|Recombinant|KO Validated

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Cytokeratin 13 antibody [EPR3671] (AB92551)

  • 5
  • 1
Primary Antibodies

AB4729

Anti-Histone H3 (acetyl K27) antibody - ChIP Grade

BOND RX™ Validated

ChIP - Anti-Histone H3 (acetyl K27) antibody - ChIP Grade (AB4729)

  • 5
  • 85
Primary Antibodies

AB128874

Anti-Brd4 antibody [EPR5150(2)]

BOND RX™ Validated|KO Validated|RabMAb|Recombinant|Lab Essentials

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Brd4 antibody [EPR5150(2)] (AB128874)

  • 5
  • 18
Cell Lines & Lysates

AB269647

Human KRT13 knockout A-431 cell lysate

Western blot - Human KRT13 knockout A-431 cell lysate (AB269647)

  • 0
  • 0
style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }
style
left-column

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

style
left-column

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab269483-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab263975 Human wild-type A-431 cell line", "number":"AB269483-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab269483 Human KRT13 knockout A-431 cell line", "number":"AB269483-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab269483-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab269483 Human KRT13 knockout A-431 cell line", "number":"AB269483-CMP01", "productcode":"" } ] } } }
style
left-column

Properties and storage information

Gene name
KRT13
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Next Generation Sequencing, Western blot
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C
style
left-column

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Cytokeratin 13 also known as KRT13 or CK13 is a type I intermediate filament protein weighing approximately 44 kDa. It is one of the cytokeratin types that plays a critical role in the mechanical stability and integrity of epithelial cells. Cytokeratin 13 is expressed in the stratified squamous epithelium particularly in the upper layers of non-cornified epithelia which include the esophagus tongue and cervix. This protein forms heteropolymers with type II keratins contributing to the cytoskeletal filament network within epithelial cells.
Biological function summary

This protein participates in maintaining the structural framework and dynamics within epithelial tissues. As part of the cytoskeletal complex cytokeratin 13 supports cellular resilience against mechanical stress. It interacts with other cytokeratins contributing to the formation of a robust keratin filament network essential for epithelial cell function and differentiation. Its expression and regulation are key to the homeostasis of the tissues where it is found ensuring proper cell division and tissue integrity.

Pathways

Cytokeratin 13 integrates into epithelial cell differentiation and repair processes. It is involved in the epithelial-mesenchymal transition (EMT) pathway important for tissue development wound healing and cancer metastasis. During the EMT process cytokeratin 13 often works alongside proteins like E-cadherin and Vimentin mediating changes in epithelial cell architecture and polarity. This modulation is essential for cellular plasticity and response to environmental cues.

Cytokeratin 13 has associations with certain epithelial tissue abnormalities such as oral squamous cell carcinoma and a subgroup of inherited blistering diseases like epidermolysis bullosa. In oral squamous cell carcinoma dysregulation of cytokeratin 13 expression may indicate tumor progression and metastasis. In epidermolysis bullosa mutations affecting keratin interactions including those with other keratins like cytokeratin 14 can lead to fragile skin and mucosal surfaces resulting in increased susceptibility to physical damage and impaired healing.
style
left-column
style
left-column

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

style
left-column

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Female

style
left-column

Product protocols

style
left-column
style
left-column
style
right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com